Application of metabolomics in the diagnosis of breast cancer: a systematic review

Yang, Liqing; Wang, Ying; Cai, Haishan; Wang, Shuang; Shen, Yueping; Ke, Chaofu

doi:10.7150/jca.37604

Cited by 60 publications

(63 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of metabolomics has dramatically expanded our understanding of the metabolic reprogramming that occurs in cancer—something that is now recognized as an important hallmark of tumors 276 . Metabolomics now represents an important new tool for noninvasive diagnosis and screening for cancer 277 . Tumors undergo lipid metabolic reprogramming that is strongly linked to malignant transformation and tumor progression.…”

Section: Discussionmentioning

confidence: 99%

Lipid metabolism in cancer progression and therapeutic strategies

Zou

Shen

et al. 2020

MedComm

178

113

View full text Add to dashboard Cite

Dysregulated lipid metabolism represents an important metabolic alteration in cancer. Fatty acids, cholesterol, and phospholipid are the three most prevalent lipids that act as energy producers, signaling molecules, and source material for the biogenesis of cell membranes. The enhanced synthesis, storage, and uptake of lipids contribute to cancer progression. The rewiring of lipid metabolism in cancer has been linked to the activation of oncogenic signaling pathways and cross talk with the tumor microenvironment. The resulting activity favors the survival and proliferation of tumor cells in the harsh conditions within the tumor. Lipid metabolism also plays a vital role in tumor immunogenicity via effects on the function of the noncancer cells within the tumor microenvironment, especially immune‐associated cells. Targeting altered lipid metabolism pathways has shown potential as a promising anticancer therapy. Here, we review recent evidence implicating the contribution of lipid metabolic reprogramming in cancer to cancer progression, and discuss the molecular mechanisms underlying lipid metabolism rewiring in cancer, and potential therapeutic strategies directed toward lipid metabolism in cancer. This review sheds new light to fully understanding of the role of lipid metabolic reprogramming in the context of cancer and provides valuable clues on therapeutic strategies targeting lipid metabolism in cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipid metabolism in cancer progression and therapeutic strategies

Zou

Shen

et al. 2020

MedComm

178

113

View full text Add to dashboard Cite

show abstract

“…It is likely that the metabolic pathways that are active in cancer cells, which allow the tumor to stay perfused and continue to grow, involve the production of biomarkers that can then be used to monitor tumor status and efficacy of therapies. These studies have indicated a correlation between metabolite profiles and disease in cancers, such as breast [54][55][56], endometrial [57], gastrointestinal (GI) [58], colorectal [59], head and neck [60], pancreatic [61,62], and bladder [63].…”

Section: Diseasementioning

confidence: 99%

Metabolomics in Radiation Biodosimetry: Current Approaches and Advances

et al. 2020

View full text Add to dashboard Cite

Triage and medical intervention strategies for unanticipated exposure during a radiation incident benefit from the early, rapid and accurate assessment of dose level. Radiation exposure results in complex and persistent molecular and cellular responses that ultimately alter the levels of many biological markers, including the metabolomic phenotype. Metabolomics is an emerging field that promises the determination of radiation exposure by the qualitative and quantitative measurements of small molecules in a biological sample. This review highlights the current role of metabolomics in assessing radiation injury, as well as considerations for the diverse range of bioanalytical and sampling technologies that are being used to detect these changes. The authors also address the influence of the physiological status of an individual, the animal models studied, the technology and analysis employed in interrogating response to the radiation insult, and variables that factor into discovery and development of robust biomarker signatures. Furthermore, available databases for these studies have been reviewed, and existing regulatory guidance for metabolomics are discussed, with the ultimate goal of providing both context for this area of radiation research and the consideration of pathways for continued development.

show abstract

“…[22][23][24][25] Similarly, plasma metabolites have been investigated as diagnostic and prognostic biomarkers in several diseases such as heart disease, 26 hepatitis, 27 Alzheimer's disease, 28 and cancer. 29,30 Similar to plasma glycans, plasma metabolites are biologically active molecules that function to regulate critical immunological responses, including in ammatory responses. [31][32][33][34] In a recent pilot study, 35 we identi ed several plasma glycomic structures whose pre-ATI levels associate with delayed viral rebound after ART discontinuation.…”

Section: Introductionmentioning

confidence: 99%

Non-Invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV

Giron

Palmer

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Non-invasive biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are urgently needed. Such biomarkers can improve the safety of analytic treatment interruption (ATI) and provide mechanistic insights into the pathways involved in post-ART HIV control. We identified plasma glycomic and metabolic signatures of time-to-viral-rebound and probability-of-viral-rebound using samples from two independent cohorts. These samples include a large number of post-treatment controllers, a rare population demonstrating sustained virologic suppression after ART-cessation. The signatures remained significant after adjusting for key demographic and clinical confounders. We also confirmed a mechanistic link between biomarkers and HIV latency reactivation and myeloid inflammation in vitro. Finally, machine learning algorithms selected sets of biomarkers that predict time-to-viral-rebound with 74–76% capacity and probability-of-viral-rebound with 97.5% capacity. In summary, we fill a major gap in HIV cure research by identifying non-invasive biomarkers, with potential functional significance, that predict duration and probability of viral remission after treatment interruption.

show abstract

Application of metabolomics in the diagnosis of breast cancer: a systematic review

Cited by 60 publications

References 94 publications

Lipid metabolism in cancer progression and therapeutic strategies

Lipid metabolism in cancer progression and therapeutic strategies

Metabolomics in Radiation Biodosimetry: Current Approaches and Advances

Non-Invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV

Contact Info

Product

Resources

About